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n INTRODUCTION
Crimean-Congo haemorrhagic fever (CCHF) is a disease state caused by Nairoviruses of 
the Bunyaviridae family, which are transmitted 
by the bites of Hyalomma marginatum ticks or by 
direct contact with infected blood or body secre-
tions. The most common clinical signs of CCHF 
are fever, nausea, headache, diarrhoea, myalgia, 
petechial rash and haemorrhage [1]. The reported 
mortality rates of CCHF epidemics and outbreaks 
vary greatly; however, the average mortality rate 
is often cited at 5-50% [2-4]. The diagnosis is es-
tablished through immunological methods, re-
verse transcription-polymerase chain reactions or 
virus isolation in the cell culture [5-7]. 
Infectious diseases can lead to haemorrhag-
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Crimean-Congo haemorrhagic fever (CCHF) is a vi-
ral zoonotic disease which can lead to life-threatening 
with haemorrhagic manifestations. We aimed here in 
this study was to evaluate the effect of the platelet 
count and volume-related indices, such as the mean 
platelet volume (MPV), platelet distribution width 
(PDW) which is a measure of platelet anisocytosis and 
plateletcrit, in the haemorrhagic manifestations and 
mortality seen in CCHF cases.
We retrospectively examined data derived from 173 
patients. The age, gender, alanine transaminase (ALT), 
aspartate transaminase (AST), platelet counts and 
MPV, PDW and PCT values upon admission (MPV1, 
PDW1 and PCT1) and those values measured at the 
time when the PLT was at the lowest level (MPV2, 
PDW2 and PCT2), haemorrhagic manifestations and 
the mortality status of patients diagnosed with CCHF 
were recorded.
ALT and AST values were higher among the haem-
orrhagic patients when compared with the others 
SUMMARY
(p<0.001), while platelet 1 (PLT1), platelet 2 (PLT2), 
plateletcrit 1 (PCT1), plateletcrit 2 (PCT2) and platelet 
distribution width 2 (PDW2) values were significantly 
lower (p=0.001, p<0.001, p=0.002, p<0.001 and p=0.003, 
respectively). A negative correlation was documented 
between haemorrhage and the PLT1, PLT2, PCT1, PCT2 
and PDW2 (r=-0.255, r=-0.415, r=-0.241, r=-0.377, r=-
0.223, respectively); however, there was a positive cor-
relation between haemorrhage and mortality (r=0.34).
This was the first study evaluating the platelet func-
tions in CCHF, such as the PLT, PDW and PCT, in 
CCHF correlated with the mortality and haemorrhag-
ic manifestations. The platelet functions contribute as 
much to the prediction of haemorrhage and mortality 
as the PLT. The present study suggests that the PCT 
and PDW values could be beneficial in anticipating the 
inclination toward haemorrhage and mortality.
Keywords: Crimean-Congo haemorrhagic fever, blood, 
platelet, mean platelet volume.
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ic manifestations by means of a constellation of 
mechanisms, including the induction of throm-
bocytopenia, depletion of local clotting factors, 
hyperfibrinolysis and leakage secondary to vessel 
wall damage [8]. However, the exact underlying 
pathogenesis behind mortality and haemorrhage 
in CCHF is yet to be completely understood. All 
of the previous studies related to CCHF have re-
ported thrombocytopoenia, elevated aspartate 
transaminase (AST) and alanine transaminase 
(ALT) levels, and a prolonged activated partial 
thromboplastin time (aPTT) as ominous prognos-
tic indicators. However, previous studies have 
yielded distinct findings with regard to the con-
tributions of leukocytosis, lactic dehydrogenase 
(LDH), creatine phosphokinase (CPK), age and 
the fibrinogen level as ominous prognostic factors 
[6-18]. 
The role platelets play lies primarily in haemosta-
sis; however, previous studies have documented 
that the platelets constitute an important compo-
nent of the immune system. Accordingly, platelets 
contribute to the immune system through vari-
ous mechanisms, such as engulfing foreign par-
ticles, giving off distinctive adhesion molecules, 
undergoing chemotaxis, triggering complement 
factors and establishing interactions with micro-
organisms. The platelet functions can be analysed 
based on the mean platelet volume (MPV), plate-
let distribution width (PDW) (which is a measure 
of platelet anisocytosis) and plateletcrit (PCT) 
(equivalent to haematocrit with regard to plate-
lets) [19]. 
Thrombocytopenia is known to be a poor prog-
nostic indicator of CCHF, and the disease may 
still pursue a mortal course despite the presence 
of an adequate number of platelets. This issue 
propelled us to consider that the platelet function 
may provide as crucial a contribution as the plate-
let count. Therefore, the aim of the present study 
was to evaluate the effect of the platelet count 
(PLT) and volume-related indices, such as the 
MPV, PCT and PDW, in the haemorrhagic mani-
festations and mortality seen in CCHF cases.
n PATIENTS AND METHODS
This study included those patients admitted to the 
Tokat State Hospital in Turkey with complaints 
of fever, anorexia, weakness, petechial rash and 
haemorrhage between April 2011 and September 
2011 and hospitalized with clinical and laborato-
ry findings compatible with CCHF, whether tick 
contact was suspected or not were enrolled in this 
study. In patients pre-diagnosed with CCHF diag-
nostic criteria were as follows; 
Clinical findings: At least two symptoms (fever, 
headache, myalgia, nausea/vomiting, arthral-
gia, weakness, haemorrhage) and leukopaenia 
(<4000/µL)/ thrombocytopaenia (<150 000/µL), 
elevation of AST, ALT), LDH and CPK.
Supportive findings: Haemorrhagic-purpuric rash 
and other haemorrhagical symptoms.
Epidemiological history and one or more of the follow-
ing exposures within the 3 weeks before onset of symp-
toms: Living in-or travel to endemic area, history 
of tick exposure, contact with blood or other body 
fluids of an animal, contact with blood or other 
body fluids of confirmed CCHF patient, work in a 
laboratory that handles CCHF specimens.
Suspected case definition: Case meets the clinical 
and epidemiologic linkage criteria.
Probable case: Case meets the clinical and epidemi-
ologic linkage criteria and meets two supportive 
findings or case meets the clinical and epidemio-
logic linkage criteria in endemic areas for CCHF.
Confirmed case: Case meets the clinical + demon-
stration of viral RNA in blood and tissue samples, 
specific IgM positivity, four-fold increase in spe-
cific IgG titre, epidemiological association with 
confirmed CCHF patient.
The serum samples of the patients were sent to 
the National Reference Laboratory for further 
analysis. The patients with PCR and/or IgM pos-
itivity suggestive of CCHF were diagnosed with 
CCHF. The platelet functions were analysed us-
ing an automated blood cell counter (Beckman 
Coulter Inc., Brea, CA, USA).
We retrospectively examined data derived from 
173 confirmed CCHF patients who were hospital-
ized.
The MPV, PDW and PCT values upon admission 
(MPV1, PDW1 and PCT1) and those values meas-
ured at the time when the PLT was at the lowest 
level (MPV2, PDW2 and PCT2) were recorded 
in all the patients. Any haemorrhagic manifesta-
tions, such as epistaxis, haematuria and vaginal 
or gastrointestinal haemorrhage, were also re-
corded.
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The categorical variables, given in counts and 
percentages, were compared between the groups 
using Pearson’s chi-squared test, and the normal-
ly distributed variables were identified using the 
Kolmogorov-Smirnov test. The continuous var-
iables, presented here in means or medians [in-
terquartile range (IQR)], were compared between 
the two groups using the two independent sample 
t test or Mann-Whitney U test. A value of P<0.05 
was accepted to imply statistical significance.
A receiver operating characteristic analysis was 
utilized in order to specify the thresholds asso-
ciated with the laboratory values with regard to 
their effects on mortality and the haemorrhagic 
manifestations. The Statistical Package for the So-
cial Sciences version 17.0 for Windows (SPSS Inc., 
Chicago, IL, USA) was used for all the statistical 
analyses.
n RESULTS
173 patients (83 males and 90 females, 47.9% and 
52.1%, respectively) and 11 deaths (6.3%) were 
identified in this study. Haemorrhaging was ob-
served in 13.8% (n=24) of these patients during 
hospitalization. When we evaluated the haem-
orrhaging with regard to the gender of the study 
participants, the WBC1, WBC2, MPV1, MPV2 and 
PDW1 values were similar between the haemor-
rhagic and non-haemorrhagic patients (p>0.05). 
In addition, there were significantly higher ALT 
and AST values among the haemorrhagic patients 
when compared with the others (p<0.001 and 
p<0.001, respectively).
When we evaluated the PLT1, PLT2, PCT1, PCT2 
and PDW2 values, they were significantly lower 
(p=0.001, p<0.001, p=0.002, p<0.001 and p=0.003, 
respectively) in the haemorrhagic patients than 
in the non-haemorrhagic patients. The laboratory 
values compared with regard to the demographic 
and clinical features are shown in Table 1. High-
er AST and ALT levels (p=0.001 and p<0.001, 
respectively) and lower PLT, PCT and PDW val-
ues (p<0.001, p<0.001 and p=0.003, respectively) 
were detected in the patients in whom mortality 
occurred, when compared to the patients that re-
covered. The lower thresholds for the PCT1 and 
PCT2 were determined to be ≤0.02 (PCT1 sensi-
tivity = 37.5% and specificity = 92.6%; PCT2 sensi-
tivity = 92.3% and specificity = 82.4%) (Figure 1). 
A negative correlation was seen between haem-
orrhage and the PLT1, PLT2, PCT1, PCT2 and 
Table 1 - Comparison of the demographic characteristics and laboratory values of the haemorrhaging and 
non-haemorrhagic patients.
Age mean±SD
Haemorrhagic patients
(N=149)
47.54±17.3
Non-haemorrhagic patients
 (N=24)
46.83±21.17
P >0.05
Male (N, %) 83 (55,7 %) 12 (50%) >0.05
WBC1 median (IQR)
WBC2 mean±SD
2400 (1900-3200)
2207±992
2500 (1835-3600)
2191±1207
>0.05
>0.05
Plt1 mean±SD
Plt2 mean±SD
90.64±38.58
61.08±35.3
60.75±37.97
23.79±15.27
0.001
<0.001
MPV 1mean±SD
MPV2 mean±SD
9.18±1.12
9.26±1.05
9.37±0.82
9.37±0.92
>0.05
>0.05
PCT1 mean ±SD
PCT2 mean (IQR)
0.08±0.03
0.05±0.03
0.05±0.03
0.05 (0.03-0.07)
0.002
<0.001
PDW1 mean±SD
PDW2 mean±SD
16.55±0.81
16.9±0.82
16.63±0.76
16.38±0.93
>0.05
0.003
ALT median (IQR)
AST median (IQR)
32.5 (21-49.25)
57.5 (33.75-113)
54 (34.5-96.75)
81.5 (64.5-163.24)
<0.001
<0.001
WBC1: Initial White blood cell count, WBC 2: Lowest White blood cell count, Plt 1: Initial platelet value, Plt 2: Lowest platelet value, MPV 1: Mean 
platelet volume, MPV 2: Lowest mean platelet value, PCT 1: Initial plateletcrit, PCT 2: Lowest plateletcrit, PDW 1: Initial platelet distribution width, 
PDW 2: Lowest platelet distribution width, PT: Prothrombine time, aPTT: Active tromboplastine time, SD: Standart deviation, IQR: Interquartile 
range, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase
Normal values: WBC: 4. 800-10.800 mm3, Platelet: 150000-400000 mm3, MPV 6.5-12 fL, PCT: 0.108-0.282%, PDW: 10-65%, PT: 10-14 sec., APTT: 21-36 
sec., AST: 15-37 IU/L, ALT: 30-65 IU/L
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PDW2 (r=-0.255, r=-0.415, r=-0.241, r=-0.377 and 
r=-0.223, respectively); however, there was a pos-
itive correlation between haemorrhage and mor-
tality (r=0.34).
n DISCUSSION
The first CCHF case in Turkey was reported in To-
kat province located in Kelkit Valley in 2002, how-
ever earlier reports of serologically confirmed cas-
es were available from Turkey and neighboring 
countries [19]. Since then, CCHF has been endem-
ic in Tokat and in Turkey. Because of this reason 
the number of cases were significantly high in a 
very short period of time in our study. 
There are some typical biochemical and hemato-
logical changes in CCHF patients. Thrombocy-
topenia, leukopenia, AST, ALT, LDH, and CPK 
elevation, aPTT and PT prolongation, INR eleva-
tion, and a decrease in fibrinogen are observed 
in these patients [4, 13]. Numerous studies have 
been shown that, low platelet counts, prolonga-
tion of aPTT and PT, and elevated INR values 
were found to be significant markers used in both 
the diagnosis and follow-up of CCHF cases. Our 
clinical and laboratory results are consistent with 
those previously reported with regard to CCHF 
disease. A high WBC count was found to be sig-
nificant only in the study conducted by Swanep-
oel et al., but not in the other studies and in our 
Figure 1 - Receiver operating characteristic analysis of 
the plateletcrit at the lowest platelet count and mor-
tality.
study [8,11-15].
A PLT count <20x109/mL has been reported to be 
an indicator of a poor prognosis The platelet func-
tions, such as the PLT, PDW and PCT, in CCHF 
correlated with the mortality and haemorrhagic 
manifestations in our study which was compati-
ble with previously reported results in the litera-
ture [6, 8, 12-17, 20, 21].
Yilmaz et al. found that the PDW could be used to 
determine the disease severity [21]. In addition, 
Onguru et al. evaluated the correlations between 
mortality and the coagulation-related parameters 
in CCHF, such as proteins C and S, antithrombin 
III, activated protein C resistance and D-dimer 
results [17]. Reporting no correlations in the for-
mer, they announced the existence of an associ-
ation between mortality and several parameters, 
including the platelet count, prothrombin time, 
aPTT, international normalized ratio and fibrin-
ogen levels, and that the traditional coagulation 
parameters were sufficient for monitoring during 
the diagnosis and follow-up.
There are three major components of haemosta-
sis: primary haemostasis, secondary haemostasis 
and fibrinolysis [21]. Primary haemostasis can be 
evaluated via a complete or full blood count, and 
a test to provide data regarding the PLT and plate-
let volume, morphology and maturity has been 
evaluated [21, 22]. Modern blood counters can be 
used for the rapid measurement of these parame-
ters, including the MPV, PDW and PCT.
A sizable number of compounds contributing to 
inflammation, coagulation, thrombosis and ath-
erosclerosis are secreted from activated platelets, 
including chemokines, cytokines and coagulation 
factors. Previous clinical trials have indicated that 
platelets are a pivotal component in the evalua-
tion of the inflammatory response, and the afore-
mentioned factors play roles in aggregation, ad-
hesion and thrombus generation [23]. The platelet 
volume increases upon activation, with larger 
platelets documented to possess thrombotic po-
tential and induce inflammatory processes [24].
The platelet size is dictated by progenitor cells, 
such as megakaryocytes, and some studies have 
suggested that cytokines like interleukin (IL)-
3 and IL-6 stimulate the megakaryocytes at the 
chromosomal level, thus augmenting the pro-
duction of much more reactive and voluminous 
platelets [25]. The MPV indicates platelet activa-
tion, and it is an important marker predicting the 
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function, morphology and maturity of the plate-
lets. The MPV is provided by a complete blood 
count, creating no further costs for its measure-
ment [26]. For reliable MPV measurement, the po-
tential influence of anticoagulant or standardiz-
ing the time delay between sampling and analysis 
[27]. The MPV level has been shown to increase 
during inflammatory disease states, including an-
kylosing spondylitis, rheumatoid arthritis and in-
fectious diseases like pulmonary tuberculosis [28, 
29]. Ekiz et al. reported that significant increase in 
MPV was observed in patients with CCHF com-
pared with healthy controls but the MPV levels 
were found to be normal in this study [16]. At 
this point, we considered that these two opposite 
issues were related to CCHF itself, which is an 
infectious disease characterized by thrombocyto-
penia, and cancelled each other out, sustaining a 
normal MPV range. 
The limit at which platelet transfusion should be 
commenced remains to be elucidated. Our clinical 
experiences yield conflicting data, ranging from 
cases of haemorrhage with PLTs >50,000 to oth-
ers with PLTs <20,000 without any overt haemor-
rhage. Representing a more precious indicator in 
terms of haemorrhage risk when compared to the 
PLT, a PCT value <0.1% dictates the implementa-
tion of a thrombocyte transfusion [30]. 
The present study found correlations between a 
decreasing PTC and haemorrhage and mortality 
during the CCHF follow-up. We consider that the 
PCT value may prove useful in the anticipation 
of the platelet transfusion timing in patients with 
CCHF. Similar to the concept of the erythrocyte 
distribution range, the PDW represents an index 
indicating the heterogeneity of the platelet vol-
umes. An evaluation of the PWD along with the 
MPV provides a better estimation of the platelet 
volume distribution. For example, it has been 
shown that the PDW is greater in patients with 
activated platelets when compared with healthy 
subjects [31].
The PDW, similar to the MPV, has been report-
ed to increase in patients with platelet activation 
when compared with healthy subjects. Moreover, 
it was suggested that the PDW acted more spe-
cifically when compared to the MPV. Contrarily, 
the MPV and PDW are generally measured at 
the lower limits during thrombocytopenic states 
caused by bone marrow failure. We believe that 
use of the MPV and PDW in combination is likely 
to yield a more accurate prediction of the coagu-
lation activation [32]. 
The PDW values measured upon admission were 
normal, whereas the levels measured at the time 
of the lowest platelet count (PDW2) were found to 
be lower. The decrease in the PDW, measured to 
be normal at the onset of the disease, in a parallel 
manner to the deterioration of the disease, sug-
gests that the PDW2 may be associated with haem-
orrhage and mortality, and that it can be used in 
predicting thrombocyte activation as a prognostic 
indicator during the follow-up of this disease.
Sharifi-Mood et al. reported that high-dose meth-
ylprednisolone is effective in the treatment of pa-
tients with CCHF and its effect on thrombocyte 
activation. Further investigation is necessary in 
order to determine the  efficacy  of corticosteroid 
and its effect on outcome [33].
n CONCLUSION
Haemorrhage is one of the most important reasons 
for mortality in CCHF cases. The platelet functions 
contribute as much to the prediction of haemor-
rhage and mortality as the PLT. The present study 
suggests that the PCT and PDW values could be 
beneficial in anticipating the inclination toward 
haemorrhage and mortality, beginning from the 
onset of the disease and from the time when the 
PLT begins to decrease, respectively. We suggest 
that certain parameters, like the PCT and PDW, 
which are included in the CBC test and do not in-
cur additional costs to measure, may be utilized in 
the follow-up of CCHF patients, and that further 
studies are likely to help elucidate this issue.
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